Scalper1 News
Cancer therapies and bullish earnings forecasts took the spotlight Monday at the opening of JPMorgan’s Healthcare Conference this week in San Francisco, one of the largest annual biotech conferences worldwide. Celgene (CELG) provided a bullish forecast for its cancer drug Revlimid, along with generally positive preliminary Q4 results and long-term financial outlook. Bristol-Myers Squibb (BMY) announced positive-trial results for Scalper1 News
Scalper1 News